Scientists deliberately infect volunteers with whooping cough to speed up vaccine development
NCT ID NCT06827470
First seen Jan 07, 2026 · Last updated May 22, 2026 · Updated 17 times
Summary
This study aims to create a safe, controlled human infection model for whooping cough. About 60 healthy adults aged 18-50 will receive a nasal spray containing a low dose of the bacteria. Researchers will monitor how many develop mild symptoms and test nasal samples to find the safest dose that reliably causes infection. This will help test future vaccines and treatments more efficiently.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERTUSSIS (WHOOPING COUGH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Canadian Center for Vaccinology
RECRUITINGHalifax, Nova Scotia, B3K 6R8, Canada
Conditions
Explore the condition pages connected to this study.